Shares in Novo Nordisk (NYSE:NVO) fell today after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results.
The Denmark-based company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Shares in Novo Nordisk sink after Q4 earnings, sales disappoint appeared first on MassDevice.